Fagö-Olsen Carsten Lindberg, Ottesen Bent, Kehlet Henrik, Antonsen Sofie Leisby, Christensen Ib Jarle, Markauskas Algirdas, Mosgaard Berit Jul, Ottosen Christian, Sogaard Charlotte Hasselholt, Hoegdall Claus
*Department of Gynecology, †Section of Surgical Pathophysiology; ‡The Finsen Laboratory and Biotech Research and Innovation Center, Rigshospitalet, Copenhagen University Hospital, Copenhagen; §Department of Gynecology and Obstetrics, Odense University Hospital, Odense; ∥Department of Gynecology and Obstetrics, Herlev Hospital, Copenhagen University Hospital, Copenhagen; and ¶Department of Gynecology and Obstetrics, Aarhus University Hospital, Aarhus, Denmark.
Int J Gynecol Cancer. 2014 Sep;24(7):1195-205. doi: 10.1097/IGC.0000000000000200.
Triage of patients with ovarian cancer to primary debulking surgery (PDS) or neoadjuvant chemotherapy (NACT) is challenging. In Denmark, the use of NACT has increased, but substantial differences in the use of NACT or PDS exist among centers. We aimed to characterize the differences between intended and actual first-line treatments in addition to the differences in the triage process among the centers and to evaluate the different diagnostic modalities and the clinical aspects' influence in the triage process.
From 4 centers, forms containing data about the diagnostic process and intended treatment were prospectively collected and merged with data from the Danish Gynecological Cancer Database and medical records.
Of the 671 completed forms, 540 patients had stage IIIC or IV epithelial ovarian cancer. Of the 238 (44%) referred to PDS, 91% received PDS and 4% never had debulking surgery. Of the 288 patients (53%) referred to NACT, 44% were never debulked. Fourteen patients (3%) were referred to palliative treatment. The use of different imaging modalities, diagnostic laparoscopy, and laparotomy varied significantly among the centers. Diagnostic surgical procedures were considered to be most influential in the triage process. Regardless of the intended first-line treatment or center, the tumor size and dissemination was the most influential clinical aspect.
In Denmark, substantial differences exist between intended and actual first-line treatments as well as in the diagnostic process and use of NACT, calling for further discussion on diagnostic strategy and therapeutically approach for patients with advanced ovarian cancer.
将卵巢癌患者分流至初次肿瘤细胞减灭术(PDS)或新辅助化疗(NACT)具有挑战性。在丹麦,NACT的使用有所增加,但各中心在NACT或PDS的使用上存在显著差异。我们旨在描述预期与实际一线治疗之间的差异以及各中心在分流过程中的差异,并评估不同诊断方式和临床因素在分流过程中的影响。
前瞻性收集来自4个中心的包含诊断过程和预期治疗数据的表格,并与丹麦妇科癌症数据库及病历数据合并。
在671份填好的表格中,540例患者患有IIIC期或IV期上皮性卵巢癌。在转诊至PDS的238例患者(44%)中,91%接受了PDS,4%从未接受过肿瘤细胞减灭术。在转诊至NACT的288例患者(53%)中,44%从未接受过肿瘤细胞减灭术。14例患者(3%)被转诊至姑息治疗。各中心在不同成像方式、诊断性腹腔镜检查和剖腹手术的使用上存在显著差异。诊断性手术操作被认为在分流过程中影响最大。无论预期的一线治疗或中心如何,肿瘤大小和播散是最具影响力的临床因素。
在丹麦,预期与实际一线治疗之间以及NACT的诊断过程和使用方面存在显著差异,这需要对晚期卵巢癌患者的诊断策略和治疗方法进行进一步讨论。